Durvalumab-680LT is currently being used in a first-in-human study (NCT05450484) at the University Medical Center Groningen to assess the tumour heterogeneity of PD-L1 expression in oesophageal cancer before and after neoadjuvant chemoradiotherapy. This evidence concerns the gene CD274 and carcinoma of esophagus.